JP2022517433A5 - - Google Patents
Info
- Publication number
- JP2022517433A5 JP2022517433A5 JP2021541666A JP2021541666A JP2022517433A5 JP 2022517433 A5 JP2022517433 A5 JP 2022517433A5 JP 2021541666 A JP2021541666 A JP 2021541666A JP 2021541666 A JP2021541666 A JP 2021541666A JP 2022517433 A5 JP2022517433 A5 JP 2022517433A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- weight
- cgrp antagonist
- breakthrough
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794665P | 2019-01-20 | 2019-01-20 | |
| US62/794,665 | 2019-01-20 | ||
| US201962844169P | 2019-05-07 | 2019-05-07 | |
| US62/844,169 | 2019-05-07 | ||
| US201962893206P | 2019-08-29 | 2019-08-29 | |
| US62/893,206 | 2019-08-29 | ||
| US201962910284P | 2019-10-03 | 2019-10-03 | |
| US62/910,284 | 2019-10-03 | ||
| US202062959088P | 2020-01-09 | 2020-01-09 | |
| US62/959,088 | 2020-01-09 | ||
| PCT/US2020/014239 WO2020150703A1 (en) | 2019-01-20 | 2020-01-19 | Cgrp antagonists for treating migraine breakthrough |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022517433A JP2022517433A (ja) | 2022-03-08 |
| JP2022517433A5 true JP2022517433A5 (cg-RX-API-DMAC7.html) | 2022-09-22 |
Family
ID=71613964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541666A Pending JP2022517433A (ja) | 2019-01-20 | 2020-01-19 | 突出性の片頭痛を処置するためのcgrpアンタゴニスト |
Country Status (13)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| DK4088720T3 (da) * | 2018-03-25 | 2025-09-29 | Pfizer Ireland Pharmaceuticals Unlimited Company | Rimegepant til cgrp-relaterede lidelser |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| TW202019459A (zh) * | 2018-07-05 | 2020-06-01 | 愛爾蘭商歐樂根製藥國際有限公司 | Cgrp拮抗劑及梭菌衍生物之組合療法 |
| WO2021005494A1 (en) * | 2019-07-05 | 2021-01-14 | Allergan Pharmaceuticals International Limited | Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders |
| JP2022549167A (ja) | 2019-09-18 | 2022-11-24 | マサチューセッツ インスティテュート オブ テクノロジー | 鋭いエッジを生産するためのシステム、組成物、および方法 |
| EP4034156A4 (en) * | 2019-09-25 | 2024-01-24 | Allergan Pharmaceuticals International Limited | COMBINATION THERAPY WITH CGRP ANTAGONISTS |
| MX2023001071A (es) | 2020-07-29 | 2023-05-12 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
| CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
| CA3202137A1 (en) * | 2020-11-19 | 2022-05-27 | Pfizer Ireland Pharmaceuticals | Compositions for improved delivery of cgrp inhibitors |
| IT202000029459A1 (it) * | 2020-12-03 | 2022-06-03 | Alberto Chiarugi | Terapia dei disturbi emotivi |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| JP2024505509A (ja) * | 2021-02-01 | 2024-02-06 | ファイザー アイルランド ファーマシューティカルズ | Cgrp阻害薬の医薬組成物およびそれらを使用する方法 |
| CN117999078A (zh) * | 2021-03-02 | 2024-05-07 | Cgrp诊断公司 | 偏头痛的发生的治疗和/或降低 |
| WO2023034466A1 (en) * | 2021-09-02 | 2023-03-09 | Pfizer Ireland Pharmaceuticals | Cgrp antagonists for treating psoriasis |
| JP2024533756A (ja) | 2021-09-27 | 2024-09-12 | アラガン ファーマスーティカルズ インターナショナル リミテッド | アトゲパントを含む片頭痛の併用療法 |
| US20240366618A1 (en) * | 2021-10-11 | 2024-11-07 | Pfizer Ireland Pharmaceuticals | CGRP Antagonists for Treating Trigeminal Neuralgia |
| CN114053232A (zh) * | 2021-11-23 | 2022-02-18 | 莱默(北京)药业科技有限公司 | 一种乌布吉泮冻干口崩片及制备方法 |
| WO2023177823A1 (en) * | 2022-03-17 | 2023-09-21 | Vasoceuticals, Inc. | Combined use of individual compounds for treatment of chronic pain disorders |
| US20240358695A1 (en) * | 2023-04-25 | 2024-10-31 | Aurobindo Pharma Ltd | Pharmaceutical Compositions of Rimegepant |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| US8481546B2 (en) * | 2010-03-30 | 2013-07-09 | Bristol-Myers Squibb Company | CGRP receptor antagonist |
| RS56556B1 (sr) * | 2012-02-27 | 2018-02-28 | Bristol Myers Squibb Co | N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h- imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna so |
| SMT202600087T1 (it) * | 2016-09-23 | 2026-03-09 | Teva Pharmaceuticals Int Gmbh | Trattamento dell’emicrania refrattaria |
| US20180092899A1 (en) * | 2016-09-30 | 2018-04-05 | Merck Sharp & Dohme Corp. | Method of treating acute migraine with cgrp-active compound |
| TWI754772B (zh) * | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| DK4088720T3 (da) * | 2018-03-25 | 2025-09-29 | Pfizer Ireland Pharmaceuticals Unlimited Company | Rimegepant til cgrp-relaterede lidelser |
| US20190374518A1 (en) * | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| TW202019459A (zh) * | 2018-07-05 | 2020-06-01 | 愛爾蘭商歐樂根製藥國際有限公司 | Cgrp拮抗劑及梭菌衍生物之組合療法 |
-
2020
- 2020-01-19 KR KR1020217025959A patent/KR20210116560A/ko not_active Withdrawn
- 2020-01-19 CN CN202080009963.1A patent/CN113316470A/zh active Pending
- 2020-01-19 CA CA3127328A patent/CA3127328A1/en active Pending
- 2020-01-19 EP EP20741046.5A patent/EP3911409A4/en not_active Withdrawn
- 2020-01-19 US US17/269,227 patent/US20210338654A1/en not_active Abandoned
- 2020-01-19 WO PCT/US2020/014239 patent/WO2020150703A1/en not_active Ceased
- 2020-01-19 AU AU2020210024A patent/AU2020210024A1/en not_active Abandoned
- 2020-01-19 BR BR112021011546-3A patent/BR112021011546A2/pt not_active Application Discontinuation
- 2020-01-19 MX MX2021008191A patent/MX2021008191A/es unknown
- 2020-01-19 SG SG11202106721VA patent/SG11202106721VA/en unknown
- 2020-01-19 JP JP2021541666A patent/JP2022517433A/ja active Pending
- 2020-01-19 PH PH1/2021/551689A patent/PH12021551689A1/en unknown
-
2021
- 2021-02-17 US US17/178,217 patent/US20210196699A1/en not_active Abandoned
- 2021-07-19 IL IL284947A patent/IL284947A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170216212A1 (en) | Tapentadol compositions | |
| US20070184109A1 (en) | Compositions comprising triptans and nsaids | |
| CN102395276A (zh) | 硝唑尼特的控制释放药物剂型 | |
| EP1919473B1 (fr) | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte et son application therapeutique | |
| JP2012021025A (ja) | メロキシカムを含む組成物 | |
| US20080026054A1 (en) | Novel anelgesic combination | |
| JP2022516662A5 (cg-RX-API-DMAC7.html) | ||
| BG102669A (bg) | Метод за лечение и фармацевтичен състав | |
| CN1141937C (zh) | 含有曲马朵的药物组合物用于制备治疗偏头痛或类偏头痛的药物 | |
| US20210196685A1 (en) | Composition for eradicating helicobacter pylori | |
| CN1726035A (zh) | 非甾体抗炎药、解充血药和抗组胺药的组合物 | |
| WO2005094832A1 (en) | Compositions comprising meloxicam | |
| US20050038018A1 (en) | Meloxicam compositions | |
| CN120129522A (zh) | 用于治疗化脓性汗腺炎的方法和组合物 | |
| EP3432931A1 (en) | Pharmaceutical compositons for n-propargylamine derivative | |
| CN101360756A (zh) | 治疗胃肠道病症的方法和组合物 | |
| JP2024084670A5 (cg-RX-API-DMAC7.html) | ||
| JP2021518438A (ja) | 男性の避妊のための非ホルモン性組成物および方法 | |
| JP2009535336A (ja) | 片頭痛治療用の固定組合せ剤形 | |
| CN112263581A (zh) | 一种治疗pe和ed的双层片复方制剂及其制备方法 | |
| HK1047547B (en) | Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug | |
| CN115887462A (zh) | 一种口服药物组合物 | |
| RU2025133530A (ru) | Лечение бокового амиотрофического склероза (бас) | |
| WO2017100324A1 (en) | Combination therapy for treating female hypoactive sexual desire disorders | |
| ZA200509860B (en) | Composition comprising triptans and NSAIDS |